Background
==========

In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) has been legally empowered to assess the increase in benefit as well as the relationship of benefits and costs for drugs and healthcare procedures. IQWiG has recently published a working paper on cost estimation in cost--benefit assessments in Germany \[[@B1]\]. In this document, it is acknowledged that there is potential for standardization of costing methodology to improve the comparability of health economic evaluations. Lists of agreed unit costs (so-called standard cost lists) that supplement guidelines for health economic break at evaluation in other countries (e.g. Australia \[[@B2]\], Canada \[[@B3],[@B4]\], and the Netherlands \[[@B5]\]) are cited as examples of such standardization. In addition, the 'Methods in Health Economic Evaluation' Working Group (AG Methoden der gesundheitsökonomischen Evaluation \[AG MEG\]) of the German Society for Social Medicine and Prevention have developed an approach to standardizing cost estimates \[[@B6]\]. In general, however, such lists do not comprise agreed costs for frequently observed clinical events as estimates for the actual costs accrued (so-called costs for clinical events).

Costs for clinical events are essential for creating health economic models that are able to accurately simulate both the health outcomes and cost of different treatment options by incorporating evidence from a variety of sources. Ideally, the way in which these costs are obtained and the cost components included, should be described in the reporting of each study. We conducted a systematic literature review of costs for clinical events used in health economic evaluations in Germany from 2005 to 2009 in order to provide insight into the derivation of these costs and to assess the potential for providing future standard lists for clinical events.

Methods
=======

Identification of relevant studies
----------------------------------

A systematic literature review was conducted to determine the costs for clinical events that are relevant to patients with diabetes mellitus, according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) literature review methodology \[[@B7]\]. Diabetes mellitus has a significant economic burden and it was assumed that an adequate number of health economic analyses in this disease area would have been published in the time frame of interest to enable an analysis of costs to be performed. Typically such health economic models include a range of disease stages and provide invaluable insight into the derivation of costs of clinical events. In total, 24 databases, including MEDLINE, BIOSIS, the Cochrane Library and Embase (see Additional file [1](#S1){ref-type="supplementary-material"}), were searched for articles published between January 2005 and October 2009. The reference lists of systematic reviews and meta-analyses identified were screened independently by two researchers to assess whether they included health economic evaluations that met the criteria for inclusion; disagreements were resolved after discussion between the two researchers. The final search was conducted on 30 October 2009.

Articles were included in this review if they: were economic analyses reporting an incremental cost-effectiveness ratio (ICER); included German patients aged at least 18 years; were published in 2005 or later in English or German; and evaluated at least one of 11 predefined clinical events (acute myocardial infarction \[MI\], stroke, angina pectoris, heart failure, microalbuminuria and/or macroalbuminuria, renal failure, cataract, retinopathy, blindness, neuropathy, and amputation owing to diabetic foot syndrome). Only full text published articles were included in the review; abstracts referencing congress presentations were excluded. The flow of studies through the systematic review is shown in Figure [1](#F1){ref-type="fig"}.

![Flow chart of included studies.](1478-7547-10-7-1){#F1}

Information extraction and analysis
-----------------------------------

In order to examine the ability of the extracted costs to inform future standard lists for clinical events, the characteristics of the health economic evaluations (type of economic evaluation, model type, time horizon, cycle length, target population, severity of health status, type of intervention, outcome measure, perspective of analysis, primary time horizon, secondary time horizon, type of sensitivity analysis), costs for clinical events, and derivation of these costs (time horizon covered, cost compounds covered, year of cost data, currency conversion rate, inflation rate) were extracted using a Microsoft Access database structured form. The maximum and minimum costs used in Markov models that had a cycle length of 12 months were then summarized in a table, with stratification by first cycle and follow-up cycles.

Results
=======

Identification of relevant studies
----------------------------------

In total, 616 articles were identified from database searches, and one further article was identified through hand-searching of reference lists from systematic reviews and meta-analyses. Of the 617 articles identified, 485 were excluded based on the title or abstract, and a further 111 articles were excluded after evaluation of the full text; 21 articles were therefore included in the final review (Figure [1](#F1){ref-type="fig"}).

Study characteristics
---------------------

The study characteristics of the included articles are described in Table [1](#T1){ref-type="table"}. Ten articles reported cost-utility analyses, nine reported cost-effectiveness analyses, and two reported findings from both types of economic analysis. Overall, 19 analyses were undertaken from the payer perspective, one from the societal perspective, and in one article the perspective was not specified. Most articles reported the results of Markov (*n* = 12) or semi-Markov models (*n* = 5). Four articles reported results from a decision tree, two of which also included Markov modelling.

###### 

Included studies

  **Study**                              **Patients**                                             **Intervention**                             **Health states evaluated**   **Perspective**   **Time horizon**
  -------------------------------------- -------------------------------------------------------- -------------------------------------------- ----------------------------- ----------------- ------------------
  Annemans et al. 2006 \[[@B8]\]         At risk of cardiovascular disease (primary prevention)   ASA                                          · MI                          Payer             10 years
                                                                                                                                               · Stroke                                         
  Berg et al. 2007 \[[@B9]\]             STEMI                                                    Clopidogrel + ASA                            · MI                          Societal          1 year
                                                                                                                                               · Stroke                                         
  Berg et al. 2008 \[[@B10]\]            ACS undergoing PCI                                       Clopidogrel + ASA                            · MI                          Payer             Not specified
                                                                                                                                               · Stroke                                         
  Berger et al. 2008 \[[@B11]\]          Elevated risk of MI, ischaemic stroke                    Clopidogrel                                  · MI                          Payer             2 years
                                                                                                                                               · Stroke                                         
  Brüggenjürgen et al. 2007 \[[@B12]\]   ACS without ST-elevation                                 Clopidogrel + ASA                            · MI                          Payer             Lifetime
                                                                                                                                               · Stroke                                         
  Claes et al. 2008 \[[@B13]\]           Stroke                                                   Dipyridamole + ASA                           · Stroke                      Payer             Lifetime
  Gandjour et al. 2007 \[[@B14]\]        Hypertension at high or low risk for CVD                 National hypertension treatment programme    · MI                          Payer             Lifetime
                                                                                                                                               · Stroke                                         
  Jürgensen et al. 2009 \[[@B15]\]       Dialysis                                                 Immunosuppressive therapy -- sirolimus       · End-stage renal disease     Payer             2 years
  Lamotte et al. 2006 \[[@B16]\]         CVD                                                      ASA                                          · MI                          Payer             10 years
                                                                                                                                               · Stroke                                         
  Lamotte et al. 2006 \[[@B17]\]         MI                                                       n-3 PUFA post-MI                             · MI                          Payer             3.5 years
                                                                                                                                               · Stroke                                         
  Liebl et al. 2006 \[[@B18]\]           IGT                                                      Acarbose                                     · Angina pectoris             Payer             3.3 years
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Stroke                                         
  Mittendorf et al. 2009 \[[@B19]\]      Type 2 DM                                                Exenatide                                    · Angina pectoris             Payer             10 years
                                                                                                                                               · Blindness                                      
                                                                                                                                               · Cataract                                       
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Neuropathy                                     
                                                                                                                                               · Retinopathy                                    
                                                                                                                                               · Stroke                                         
  Neeser et al. 2006 \[[@B20]\]          Atrial fibrillation                                      Oral vitamin K antagonists                   · Stroke                      Not specified     10 years
  Rasch et al. 2009 \[[@B21]\]           Smoking                                                  Varenicline                                  · Stroke                      Payer             Lifetime
  Rosery et al. 2006 \[[@B22]\]          Secondary hyperparathyroidism during haemodialysis       Paricalcitol (i.v.)                          · End-stage renal disease     Payer             1 year
  Roze et al. 2006 \[[@B23]\]            Insulin-naïve type 2 DM                                  Acarbose + diet                              · Angina pectoris             Payer             35 years
                                                                                                                                               · Blindness                                      
                                                                                                                                               · Cataract                                       
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Neuropathy                                     
                                                                                                                                               · Stroke                                         
  Schaufler 2009 \[[@B24]\]              Type 2 DM                                                Type 2 DM prevention                         · Blindness                   Payer             1 year
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · MI                                             
                                                                                                                                               · Retinopathy                                    
                                                                                                                                               · Stroke                                         
  Scherbaum et al. 2009 \[[@B25]\]       Type 2 DM with macrovascular disease                     Pioglitazone                                 · Blindness                   Payer             35 years
                                                                                                                                               · Cataract                                       
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Neuropathy                                     
                                                                                                                                               · Retinopathy                                    
                                                                                                                                               · Stroke                                         
  Schwander et al. 2009 \[[@B26]\]       CVD                                                      Eprosartan                                   · Angina pectoris             Payer             Lifetime
                                                                                                                                               · MI                                             
                                                                                                                                               · Stroke                                         
  Valentine et al. 2008 \[[@B27]\]       Type 2 DM                                                Insulin detemir ± oral antidiabetic agents   · Angina pectoris             Payer             35 years
                                                                                                                                               · Blindness                                      
                                                                                                                                               · Cataract                                       
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Neuropathy                                     
                                                                                                                                               · Stroke                                         
  Weber et al. 2007 \[[@B28]\]           Type 2 DM                                                Self-measurement of blood glucose            · Blindness                   Payer             8 years
                                                                                                                                               · Cataract                                       
                                                                                                                                               · Diabetic foot syndrome                         
                                                                                                                                               · End-stage renal disease                        
                                                                                                                                               · Heart failure                                  
                                                                                                                                               · MI                                             
                                                                                                                                               · Neuropathy                                     
                                                                                                                                               · Retinopathy                                    
                                                                                                                                               · Stroke                                         

**ACS** = acute coronary syndromes; **ASA** = acetylsalicylic acid; **CVD** = cardiovascular disease; **DM** = diabetes mellitus; **IGT** = impaired glucose tolerance; **i.v.** = intravenous; **MI** = myocardial infarction; **PCI** = percutaneous coronary intervention; **PUFA** = polyunsaturated fatty acids; **STEMI** = ST-elevation myocardial infarction.

Information extraction and analysis
-----------------------------------

In total, 199 costs for clinical events were identified. Details on costs for acute MI and stroke are shown in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}, respectively; details on costs for all other clinical events are provided in Additional file [2](#S2){ref-type="supplementary-material"}. The year of costing and the time horizon covered were available for 194 (97%) and 163 (82%) costs, respectively. The cost components covered (e.g., hospitalization, rehabilitation) were specified for only 32 costs (16%); the inflation rate applied was not reported in any of the studies. In most cases (*n* = 140 \[70%\]), the costs were based on a single literature source. Multiple sources were cited for 32 costs; however, information on data synthesis was not reported. Sources were not stated for 27 costs (14%). Journal articles were the most common source for the derivation of costs (*n* = 153 \[77%\]), followed by healthcare system reports (*n* = 30 \[15%\]) and web pages (*n* = 24 \[12%\]). Of the 35 journal articles that were cited, 19 were cost-of-illness studies (54%).

###### 

Costs for acute myocardial infarction, 2003--2007, Germany

  **Study**                                                             **Model type**                   **Specification of disease severity**   **First cycle**     **Costs covered**   **Follow-up cycles**                                                                   
  --------------------------------------------------------------------- -------------------------------- --------------------------------------- ------------------- ------------------- ---------------------- ----- ----- ----- ----- ------------------------------- ------- ------
  **Year of costing: 2003**                                                                                                                                                                                                                                                     
  Annemans L. Int J Clin Pract 2006; 60(9): 1129--37 \[[@B8]\]          Markov model                     Fatal MI                                Not specified       2,880               1                                        Yes   No follow-up costs considered           
  Lamotte M. Pharmacoeconomics 2006; 24(2): 155--69 \[[@B16]\]          Markov model                     Fatal MI                                Not specified       2,880               NA                     Yes                     No follow-up costs considered           
  Annemans L. Int J Clin Pract 2006; 60(9): 1129--37 \[[@B8]\]          Markov model                     Non-fatal MI                            Not specified       3,123               1                                        Yes   Annual follow-up costs          1,907   1
  Lamotte M. Pharmacoeconomics 2006; 24(2): 155--69 \[[@B16]\]          Markov model                     Non-fatal MI                            Not specified       3,123               NA                     Yes                     Annual follow-up costs          1,907   1
  Liebl A. Gesund ökon Qual Manag 2006; 11: 105--11 \[[@B18]\]          Decision tree                    MI                                      Not specified       5,878               1                      Yes                     Follow-up: rehabilitation       1,261   \> 1
                                                                                                                                                                                                                                        Annual follow-up costs          1,012   \> 1
  **Year of costing: 2004**                                                                                                                                                                                                                                                     
  Lamotte M. Pharmacoeconomics 2006; 24(8): 783--95 \[[@B17]\]          Decision tree                    Fatal MI                                Acute period        2,880               1                      Yes                     No follow-up costs considered           
                                                                                                         Non-fatal MI                            Acute period        3,123               1                      Yes                     No follow-up costs considered           
  Gandjour A. Health Policy 2007; 83(2--3): 257--67 \[[@B14]\]          Markov model                     MI                                      First 12 months     4,618               \> 1                                     Yes   Post-year 1                     2,014   \> 1
  Brüggenjürgen B. Eur J Health Econ 2007; 8(1): 51--7 \[[@B12]\]       Markov model                     MI                                      First 12 months     11,241              1                      Yes   Yes   Yes         Annual follow-up costs          1,006   1
  Roze S. Curr Med Res Opin 2006; 22(7): 1415--24 \[[@B23]\]            Semi-Markov model                MI                                      Year of event       15,011              \> 1                                     Yes   Annual follow-up costs          1,168   1
  **Year of costing: 2005**                                                                                                                                                                                                                                                     
  Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 \[[@B25]\]             Semi-Markov model                Silent MI                               Year of event       0                   NA                                       Yes   No follow-up costs considered            
  Berg J. Clin Ther 2007; 29(6): 1184--202 \[[@B9]\]                    Decision tree and Markov model   MI                                      Month 1             6,799               \> 1                                     Yes   Months 2--12                    5,129   1
  Berger K. Curr Med Res Opin 2008; 24(1): 267--74 \[[@B11]\]           Markov model                     MI                                      Initial treatment   7,522               1                                  Yes         First 6 months after event      2,235   1
                                                                                                                                                                                                                                        Second 6 months after event     1,484   1
                                                                                                                                                                                                                                        Subsequent 6- month intervals   759     1
  Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 \[[@B25]\]             Semi-Markov model                Excluded silent MI                      Year of event       8,635               1                                        Yes   Annual follow-up costs          3,647   1
  Weber CJ. Diabetes Sci Technol 2007; 1(5): 676--84 \[[@B28]\]         Markov model                     MI                                      Year of event       16,767              1                                        Yes   Year after event                1,253   1
  **Year of costing: 2006**                                                                                                                                                                                                                                                     
  Valentine WJ. Adv Ther 2008; 25(6): 567--84 \[[@B27]\]                Semi-Markov model                MI                                      Year of event       15,816              \> 1                                     Yes   Annual follow-up costs          1,230   \> 1
  Schaufler TM. Gesund ökon Qual Manag 2009; 14: 71--5 \[[@B24]\]       Markov model                     MI                                      First 12 months     17,556              1                                        Yes   Annual follow-up costs          2,323   1
  Berg J. Curr Med Res Opin 2008; 24(7): 2089--101 \[[@B10]\]           Decision tree and Markov model   MI                                      Month 1             6,899               \> 1                                     Yes   Months 2--12                    5,204   1
                                                                                                                                                                                                                                        Annual follow-up costs          2,035   1
  **Year of costing: 2007**                                                                                                                                                                                                                                                     
  Mittendorf T. Diabetes Obes Metab 2009; 11(11): 1068--79 \[[@B19]\]   Semi-Markov model                MI                                      Year of event       8,614               1                                        Yes   Annual follow-up costs          1,292   NA
  Schwander B. Value Health 2009; 12(6): 857--71 \[[@B26]\]             Markov model                     MI                                      First 12 months     11,683              \> 1                                     Yes   Annual follow-up costs          2,803   \> 1

^a^ Number of data sources from which unit costs were retrieved.

^b^ No indirect unit costs could be retrieved.

**hosp** = hospital*;***MI** = myocardial infarction; **NA** = not available; **rehab** = rehabilitation.

###### 

Costs for stroke, 2003--2007, Germany

  **Study**                                                             **Model type**                   **Specification of disease severity**   **First cycle**                     **Costs covered**                     **Follow-up cycles**                                              
  --------------------------------------------------------------------- -------------------------------- --------------------------------------- ------------------- -------- ------ ------------------- ----- ----- ----- ------------------------------------------------------- -------- ------
  **Year of costing: 2003**                                                                                                                                                                                                                                                                 
  Annemans L. Int J Clin Pract 2006; 60(9): 1129--37 \[[@B8]\]          Markov model                     Fatal stroke                            Not specified       1,897    1                                      Yes   No follow-up costs considered                                    
  Lamotte M. Pharmacoeconomics 2006; 24(2): 155--69 \[[@B16]\]          Markov model                     Fatal stroke                            Acute period        1,897    NA     Yes                                   No follow-up costs considered                                    
  Annemans L. Int J Clin Pract 2006; 60(9): 1129--37 \[[@B8]\]          Markov model                     Non-fatal stroke                        Not specified       3,390    1                                      Yes   Annual follow-up costs                                  676      1
  Lamotte M. Pharmacoeconomics 2006; 24(2): 155--69 \[[@B16]\]          Markov model                     Non-fatal stroke                        Not specified       3,390    NA     Yes                                   Annual follow-up costs                                  676      1
  Liebl A. Gesund ökon Qual Manag 2006; 11: 105--11 \[[@B18]\]          Decision tree                    Stroke                                  First 3 months      12,068   1                                      Yes   Months 4--12                                            1,491    1
                                                                                                                                                                                                                           Annual follow-up costs                                  520      \> 1
  **Year of costing: 2004**                                                                                                                                                                                                                                                                 
  Lamotte M. Pharmacoeconomics. 2006; 24(8): 783--95 \[[@B17]\]         Decision tree                    Stroke                                  Acute period        3,390    1      Yes                                   No follow-up costs considered                                     
  Roze S. Curr Med Res Opin 2006; 22(7): 1415--24 \[[@B23]\]            Semi-Markov model                Fatal stroke                            Not specified       9,006    1                                      Yes   No follow-up costs considered                                     
  Rasch A. Suchtmed 2009; 11(2): 47--55 \[[@B21]\]                      Markov model                     Stroke                                  First 12 months     10,149   \> 1                                   Yes   Annual follow-up costs                                  4,364    \> 1
  Brüggenjürgen B. Eur J Health Econ 2007; 8(1): 51--7 \[[@B12]\]       Markov model                     Stroke                                  First 12 months     17,734   1      Yes                 Yes   Yes         Annual follow-up costs                                  5,614    1
  Roze S. Curr Med Res Opin 2006; 22(7): 1415--24 \[[@B23]\]            Semi-Markov model                Stroke                                  Year of event       19,399   1                                      Yes   Annual follow-up costs                                  6,060    1
  Gandjour A. Health Policy 2007; 83(2--3): 257--67 \[[@B14]\]          Markov model                     Stroke                                  First 12 months     24,936   \> 1                                   Yes   Post-year 1                                             5,465    \> 1
  **Year of costing: 2005**                                                                                                                                                                                                                                                                 
  Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 \[[@B25]\]             Semi-Markov model                TIA                                     Year of event       2,354    NA     Yes                                   Annual follow-up costs                                  0        NA
  Claes C. Med Klin 2008; 103: 778--87 \[[@B13]\]                       Markov model                     Fatal stroke                            Acute period        2,500    NA     Yes                                   No follow-up costs considered                                     
  Claes C. Med Klin 2008; 103: 778--87 \[[@B13]\]                       Markov model                     Stroke                                  Acute period        7,000    NA     Yes                                   Rehab after acute event                                 7000     NA
  Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 \[[@B25]\]             Semi-Markov model                Stoke                                   Year of event       10,524   \> 1                                   Yes   Annual follow-up costs                                  6,178    \> 1
  Weber CJ. Diabetes Sci Technol 2007; 1(5): 676--84 \[[@B28]\]         Markov model                     Stroke                                  Year of event       20,811   1                                      Yes   Year after event                                        6,501    1
  Berger K. Curr Med Res Opin 2008; 24(1): 267--74 \[[@B11]\]           Markov model                     Stroke                                  Initial treatment   4,692    NA                                     Yes   First 6 months after event                              6,664    NA
                                                                                                         Stroke                                                                                                            Second 6 months after event                             5,936    NA
                                                                                                         Stroke                                                                                                            Subsequent 6- month intervals                           5,251     
  Berg J. Clin Ther 2007; 29(6): 1184--202 \[[@B9]\]                    Decision tree and Markov model   Stroke                                  Month 1             6813     1                                      Yes   Months 2--12                                            12,112   1
                                                                                                         Stroke                                                                                                            Annual follow-up costs                                  5,600    1
  **Year of costing: 2006**                                                                                                                                                                                                                                                                 
  Valentine WJ. Adv Ther 2008; 25(6): 567--84 \[[@B27]\]                Semi-Markov model                Fatal stroke                            Not specified       9,488    1                                      Yes   No follow-up costs considered                                     
  Schaufler TM. Gesund ökon Qual Manag 2009; 14: 71--5 \[[@B24]\]       Markov model                     Stroke                                  First 12 months     18,649   1                                      Yes   Annual follow-up costs                                  4,416    1
  Valentine WJ. Adv Ther 2008; 25(6): 567--84 \[[@B27]\]                Semi-Markov model                Stroke                                  Year of event       20,439   1                                      Yes   Annual follow-up events                                 6,385    1
  Berg J. Curr Med Res Opin 2008; 24(7): 2089--101 \[[@B10]\]           Decision tree and Markov model   Stroke                                  Month 1             6,912    \> 1                                   Yes   Months 2--12                                            12,289   1
                                                                                                         Stroke                                                                                                            Annual follow-up costs                                  5,681    1
  **Year of costing: 2007**                                                                                                                                                                                                                                                                 
  Schwander B. Value Health 2009; 12(6): 857--71 \[[@B26]\]             Markov model                     TIA                                     First 12 months     3,365    \> 1                                   Yes   Annual follow-up costs                                  0        NA
                                                                                                         Stroke                                  First 12  months    17,629   \> 1                                   Yes   Annual follow-up costs                                  7,337    \> 1
  Mittendorf T. Diabetes Obes Metab 2009; 11(11): 1068--79 \[[@B19]\]   Semi-Markov model                Fatal stroke                            Year of event       19,534   1                                      Yes   No follow-up costs considered                                     
                                                                                                         Stroke                                  Year of event       19,534   1                                      Yes   Annual follow-up costs                                  5,780    1
  **Year of costing: not specified**                                                                                                                                                                                                                                                        
  Neeser K. J Kardiol 2006; 13: 131--20 \[[@B20]\]                      Markov model                     Fatal ischaemic stroke                  Not specified       3,573    1                                      Yes   No follow-up costs considered                                     
                                                                                                         Severe bleeding                         Not specified       9,000    \> 1                                   Yes   After initial hospitalization until end of first year   5,003    1
                                                                                                         Ischaemic stroke                        Acute period        4,679    1      Yes                                   From second year onwards                                12,500   1

^a^ Number of data sources from which unit costs were retrieved.

^b^ No indirect unit costs could be retrieved.

**hosp** = hospital; **rehab** = rehabilitation; **NA** = not available; **TIA** = transient ischaemic attack.

Costs for clinical events
-------------------------

There was considerable variation among the publications in the costs allocated to the clinical events of interest. This variation remained even when findings were filtered to group similar studies together. Table [4](#T4){ref-type="table"} shows the differences in the minimum and maximum costs cited for the first cycle and follow-up cycles in Markov models that had a cycle length of 12 months, and which excluded costs for fatal events, transient ischaemic attack and silent MI. Costs for each clinical event are considered in more detail below.

###### 

Costs for clinical events used in Markov models with a cycle length of 12 months

  **Health state**                                 **First cycle**   **Follow-up cycles**                         
  ------------------------------------------------ ----------------- ---------------------- -------- ---- ------- --------
  Acute myocardial infarction                      9                 4,618                  17,556   9    1,006   3,647
  Angina pectoris                                  4                 3,342                  6,840    4    1,315   6,840
  Stroke                                           10                10,149                 24,936   10   676     7,337
  Heart failure                                    4                 2,859                  6,291    3    800     2,859
  Microalbuminuria/macroalbuminuria                0                 ---                    ---      0    ---     ---
  End-stage renal disease: renal transplantation   5                 45,636                 76,135   5    9,129   11,448
  Blindness                                        4                 8,685                  11,745   2    5,331   10,661
  Retinopathy                                      3                 1,862                  3,904    1    340     340
  Cataract                                         2                 755                    1,348    1    0       0
  Neuropathy                                       5                 304                    4,091    0    ---     ---
  Diabetic foot syndrome: amputation               4                 15,405                 24,818   2    3,304   3,639

^a^ Number of event costs identified.

Costs for fatal events, silent myocardial infarction and transient ischaemic attack have been excluded.

### Acute MI

In total, 39 costs for acute MI were reported in 16 studies (Table [2](#T2){ref-type="table"}). One study included the cost of a silent MI, which was considered to be zero (0 €) \[[@B25]\]. The cost of an acute MI ranged widely. Even if only those studies that used a Markov model with a cycle length of 12 months were included (*n* = 9), the costs for the first cycle still varied considerably, ranging from 4,618 € to 17,556 € (Table [4](#T4){ref-type="table"}) \[[@B12],[@B14],[@B19],[@B23]-[@B28]\].

### Angina pectoris

Five studies reported a total of five costs for angina pectoris (Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B18],[@B19],[@B23],[@B26],[@B27]\]. First cycle costs varied widely, ranging from 3,274 € to 6,840 €. The variation in costs persisted when only those studies that used a Markov model with a cycle length of 12 months were included (Table [4](#T4){ref-type="table"}).

### Stroke

The largest number of costs was reported for stroke: 19 studies reported a total of 55 costs (Table [3](#T3){ref-type="table"}). Large variations were observed in the costs attributed to both the first and follow-up cycles for a non-fatal stroke (i.e., excluding fatal events and transient ischaemic attack). Even when only those studies that used a Markov model with a cycle length of 12 months were included, costs still varied considerably, ranging from 10,149 € to 24,936 €, and 676 € to 7,337 €, for the first and follow-up cycles, respectively (Table [4](#T4){ref-type="table"}).

### Heart failure

Six studies reported a total of seven costs for heart failure (Table [4](#T4){ref-type="table"}; Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B18],[@B19],[@B23],[@B25],[@B27],[@B28]\]. When only costs from Markov models were included, and non-serious heart failure or hospitalization-only costs were excluded, the costs for the first and follow-up cycles ranged from 2,859 € to 6,291 € and 800 € to 4,372 €, respectively \[[@B19],[@B23],[@B27],[@B28]\]; the cost components for these studies were not specified.

### Microalbuminuria and macroalbuminuria

No studies reported costs for microalbuminuria or macroalbuminuria.

### End-stage renal disease

Overall, 31 costs for end-stage renal disease were reported across eight studies (Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B15],[@B19],[@B22]-[@B25],[@B27],[@B28]\]. Costs were reported for several different levels of disease severity: renal transplantation, re-transplantation, dialysis, haemodialysis and peritoneal dialysis. End-stage renal disease had the highest reported costs of all of the clinical events evaluated in this review. In most cases, the cost components covered were not specified. The variation could not be accounted for by differences in disease severity, as it persisted when costs were categorized by transplantation (first-cycle costs 45,636--76,135 €) \[[@B19],[@B23]-[@B25],[@B27]\] or dialysis (46,296--63,696 €) \[[@B19],[@B23]-[@B25],[@B27],[@B28]\]. However, costs for follow-up cycles were consistently lower in transplantation patients than in dialysis patients (9,129--13,176 € vs. 46,296--61,230 €).

### Blindness

Eleven costs for blindness were reported across six studies (Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B19],[@B23]-[@B25],[@B27],[@B28]\]. Costs ranged from 8,685 € to 11,745 € for the first cycle, and from 5,092 € to 11,017 € for subsequent follow-up cycles. The variation in costs persisted when only those studies that used a Markov model with a cycle length of 12 months were included (Table [4](#T4){ref-type="table"}).

### Retinopathy

Only three studies gave costs for retinopathy (Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B24],[@B25],[@B28]\]. Costs for the first cycle were 1,862--3,904 €. Only one study reported costs for follow-up cycles (340 € for hospitalization) (Table [4](#T4){ref-type="table"}) \[[@B25]\].

### Cataract

Costs for cataract varied considerably (Table [4](#T4){ref-type="table"}; Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B19],[@B23],[@B25],[@B27],[@B28]\]. However, most studies did not specify the time horizon, thereby limiting the usefulness of cross-study comparisons. In addition, the cost components covered were not usually specified. Generally, studies cited only a single reference for unit cost. Two studies gave costs for hospitalization (755--1,686 €), but neither cited a source \[[@B19],[@B28]\].

### Neuropathy

Five studies reported costs for neuropathy \[[@B19],[@B23],[@B25],[@B27],[@B28]\] (Additional file [2](#S2){ref-type="supplementary-material"}). With one exception (first cycle 304 €), the costs were fairly consistent (first cycle of other four studies, 3,855--4,091 €), however, the cost components covered were not specified.

### Diabetic foot syndrome

In total, 21 costs were reported for diabetic foot syndrome, across six studies (Additional file [2](#S2){ref-type="supplementary-material"}) \[[@B19],[@B23]-[@B25],[@B27],[@B28]\]. Costs were specified for various disease severities, including gangrene, infected ulcer, uninfected ulcer, healed ulcer and amputation. Costs were almost all based on single references, and generally increased with disease severity (first-cycle costs: healed ulcer, 46--47 € \[[@B23],[@B27]\]; uninfected ulcer, 877--1,210 € \[[@B19],[@B23],[@B25],[@B27]\]; infected ulcer, 1,784--5,217 € \[[@B19],[@B23],[@B25],[@B27]\]; and gangrene, 3,186--13,056 €) \[[@B19],[@B23],[@B25],[@B27]\]. In studies that used a Markov model with a cycle length of 12 months, the cost for the first cycle for amputation ranged from 15,405 € to 24,818 € (Table [4](#T4){ref-type="table"}). The reasons for the variability in costs are unclear, as the cost components covered were not specified.

Discussion
==========

This first systematic review of costs for clinical events used in health economic evaluations in Germany shows substantial cost variability. Exact reasons for these differences are unclear, because of the generally insufficient level of methodological information regarding source data for costing of events in published health economic evaluations. The costs for clinical events published in German health economic analyses are therefore insufficient for establishing future standard lists for such events.

Our findings are consistent with the conclusions of Ray *et al.* that there is considerable internal heterogeneity in both costs and clinical values in countries lacking an established nationwide system of reporting health outcomes \[[@B29]\]. Our observation that the derivation of costs is generally not explicitly defined in German analyses was also consistent with a review of published economic evaluations available in the European Network of Health Economics Evaluation Database \[[@B30]\]. Ideally, event costs should be derived from a robust cost-of-illness study conducted in the same patient population country and setting, and with the same disease severity and treatment algorithm, as the economic evaluation. Typically, however, published cost-of-illness studies do not meet these criteria, and the derived event costs are adjusted for local differences (for example, in treatment pattern, definition of clinical event and disease severity). While this is an acceptable approach, it is essential that the methodology for adjusting the original event costs is clearly defined and supported, and that cost corrections for inflation and currency conversion are performed. Our review shows that most event costs are not based on comprehensive cost-of-illness studies, but on previous cost-effectiveness or cost-utility analyses. While this is by far the simplest approach to obtaining event costs, it raises issues as to whether the previously published cost is appropriate for the new analysis, and was itself derived appropriately.

Accurate and consistent assessment of costs is essential in countries such as Germany that are moving towards early benefit evaluations and cost--benefit analyses of new products relative to current standards of care; hence, there is a clear need to consider how the methodology for estimating costs of clinical events could be improved to ensure that health economic evaluations provide robust, realistic and comparable outputs. What methods can be applied to achieve consensus on costs for clinical events? It is clear that guidance on the derivation of costs should be fully transparent, updated regularly and in the public domain. Three alternatives can be considered.

Standard cost lists for most relevant medical/non-medical goods or services only
--------------------------------------------------------------------------------

Standard lists of agreed unit costs for medical/non-medical goods or services are provided by multiple countries, including Australia and the Netherlands, and are accompanied by guidance documents on the fundamental process for costing of events \[[@B2],[@B5]\]. This flexible approach enables the evaluation of event costs according to different perspectives and patient subgroups. In countries where healthcare systems are decentralized, cost lists may need to be developed within each major region rather than at a national level; a study in Canada showed the difficulties in consolidating cost lists across two provinces \[[@B3]\].

Standard cost models for relevant clinical events, in addition to standard cost lists for the most relevant medical/non-medical goods or services
-------------------------------------------------------------------------------------------------------------------------------------------------

A similar approach is taken by the UK National Health Service (NHS), which publishes detailed annual reports of reference costs \[[@B31]\]. The UK National Institute for Health and Clinical Excellence (NICE) mandates that economic evaluations performed for UK Health Technology Assessment describe how the clinical management of the condition is currently costed in the NHS in terms of these reference costs, and with regard to the relevant Healthcare Resource Group (HRG). This framework for developing costs of clinical events utilizing reference data provides some degree of standardization; however, it is binding only for submissions to NICE, and does not necessarily apply to independent economic evaluations that may ultimately influence decision-making. Moreover, it does not cover resource utilization or costs where the HRG is inappropriate (e.g., too broad or not reflective of resource use related to the treatment in question); in these cases, the NICE guidance document suggests using other sources of evidence, such as micro-costing studies. Such cost data may be taken from current literature, provided that the methods used to identify sources are clearly defined, and that sensitivity analysis are used to assess the implications of using alternative data sources \[[@B32]\]. A recent systematic review of primary research studies funded by the UK HTA programme showed that the majority of studies (72 out of 95 evaluated) obtained source costs from the annual compendium of Unit Costs of Health and Social Care \[[@B33]\]; 52 studies used costs that had been sourced locally (mainly NHS trusts) and 36 of the 95 studies used data from HRGs \[[@B34]\].

Standard cost lists for relevant clinical events, in addition to standard cost lists for the most relevant medical/non-medical goods or services
------------------------------------------------------------------------------------------------------------------------------------------------

A recent feasibility study confirmed the potential for developing standardized diagnosis-specific cost lists for clinical events based on publicly available actual expenditures in the German healthcare system \[[@B35]\]. Costs were derived from the Information System of the Federal Health Monitoring, utilizing the fact that official 2006 cost-of-illness accounts (<http://www.gbe-bund.de>) provide healthcare expenditures categorized according to the Organisation for Economic Co-operation and Development health accounts (ambulatory care, stationary/semi-stationary healthcare, ambulance services, administration, other providers and private households), as well as according to the three-digit codes of the International Statistical Classification of Diseases and Related Health Problems 10^th^ revision. Although increased data availability from Federal Health Monitoring will likely lead to expansion of these standard lists, this approach may prove too inflexible to take into account the divergent nature of patient populations and perspectives considered in health economic evaluations.

The strengths and limitations of the present study must be considered. Key strengths are that this was a systematic review of all available evidence, considering a clearly defined set of clinical events (related to diabetes mellitus) and studies (cost-utility and cost-effectiveness analyses) conducted from a German perspective. The analysis had a limited focus, in that it included only fully published economic analyses reporting an ICER (i.e., cost-of-illness studies were excluded); however, this was intentional in order to reflect the decision-maker perspective. A number of studies were excluded from the analysis on the basis that the results had only been published in abstract form, rather than as a full text article, indicating that there is limited access to details of country-level health economic evaluations. Other limitations include the fact that our analysis considered only 11 events within a single disease area. Although it seems reasonable to expect that the observed variability in event costs may be generalized to other disease areas, this cannot be concluded with certainty from the current study. Moreover, it was often difficult to judge whether comparisons were fair because of the lack of clarity over exactly how individual studies assessed costs and the nature of their data sources.

Conclusions
===========

This first systematic review of costs used in health economic evaluations in Germany shows substantial variability in costs for individual clinical events, and a lack of transparency and consistency in the methods used to derive those costs. Ideally, the derivation of costs for clinical events should be fully transparent, based on actual expenditure, updated regularly and in the public domain. While a full standard cost list for clinical events would not be constructive because it is unclear how costs for events vary according to patient group, perspective, and other relevant factors such as knowledge and experience in the therapeutic field of interest, the validity and cross-comparability of health economic evaluations would be considerably improved by national- or regional-level guidance on standardization of the costing methodology of individual clinical events.
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